ERYTECH to Present at JMP Securities Life Science Conference
LYON, France, June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City.
- Conference: JMP Securities Life Science Conference
- Date: June 20, 2018
- Presentation Time: 9:00 AM EDT / 3:00 CET
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-y-lyase encapsulated in red blood cells, to target cancer cells' amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Director Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
+33 1 44 71 98 52
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Erytech Pharma S.A. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
The North American Bitcoin Conference Stands Out as One of 2019’s Most Important Worldwide Crypto Events18.12.2018 15:35 | Pressemelding
MIAMI, Dec. 18, 2018 (GLOBE NEWSWIRE) -- via CryptoCurrencyWire – 2019 will kick off with what has become widely accepted as one of the most important blockchain conferences of the year. The North American Bitcoin Conference, sponsored by Keynote and part of the World Blockchain Forum, will take place Jan. 16-18, 2019, at the James L. Knight Center in Miami, Florida. This premier crypto conference, now in its seventh year, will draw cryptocurrency and blockchain leaders from all across the globe as they come together for this historical event. The North American Bitcoin Conference is the longest-running, most-attended finance conference for the blockchain and crypto industries, with each event attracting thousands of attendees. The 2019 conference will feature a lineup of more than 60 world-class presenters, including technology veterans and company founders who have collectively raised more than $18.1 billion in initial coin offerings (ICOs). Speakers that have been announced thus far
Inspirata Subsidiary, Artificial Intelligence in Medicine (AIM), Signs Contract with the National Cancer Institute (NCI) to Use Its E-Path Reporter Software for Reporting by U.S. Central Cancer Registries18.12.2018 15:06 | Pressemelding
The NCI has licensed AIM’s E-Path Reporter software for the last 15 years to provide an automated solution that enables cancer registries to more efficiently collect and report cancer incidence and survival data. Toronto, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Artificial Intelligence In Medicine Inc. (AIM), an Inspirata company, announced today that the National Cancer Institute (NCI) has extended its license agreement for AIM’s E-Path Reporter software. The software has been licensed for use within the SEER (Surveillance, Epidemiology and End Results) program, for 14 central registries and 286 major reporting hospitals and laboratories across the U.S. NCI supports cancer data collection and research through the SEER program and publishes cancer statistics for 20 U.S. geographic areas. The NCI requires participating cancer registries to collect data on cancer patient demographics, primary tumor site, tumor morphology and disease stage at diagnosis. The registries also must report on fir
Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services18.12.2018 14:30 | Pressemelding
Services and Capacity Increase with New Site Opening SAN DIEGO, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently announced the expansion of its existing translational oncology research capacity by opening a new site in Suzhou, Jiangsu, China. The large amount of data now available from preclinical and clinical research requires specialized expertise in bioinformatics, big data analysis and dedicated storage facilities. CrownBio’s new site will focus on integrating the company’s experience in preclinical and translational research with cutting-edge digital technologies for the discovery of predictive biomarkers and the development of new and companion diagnostics. The Suzhou site will become CrownBio’s center of excellence for systems biology and clinical sample testing. Located at the heart of the Bi
Family of Constant-Current Dimmable Buck LED Drivers18.12.2018 11:00 | Pressemelding
1.5A, 3A Buck LED Drivers Target ISO26262 automotive and industrial applications MILPITAS, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AMS, the Analog Mixed-Signal division of ISSI, has introduced a family of switching buck LED Drivers for automotive and industrial applications. This family of highly integrated switching constant current buck LED Drivers are targeted for 12V/24V battery connected, space-constrained, electromagnetic (EMC) sensitive applications such as Headlight, Front and Rear Fog lights, Day time Running lights to name a few. The device family supports a wide DC voltage input range of 4.5V to 38V and outputs a 5% regulated current of 1.5A or 3A; depending on the particular device, see table. The integrated power MOSFET is configured to switch in the constant on-time mode delivering true average current. Switching at a frequency of up to 2MHz which is adjustable with an external resistor, these buck LED Drivers can use smaller output inductor and capacitor values thereby
John Charman Appointed Chief Executive Officer of Sompo Holdings Overseas Insurance Business and Nigel Frudd Appointed as Chief Executive Officer of Sompo International18.12.2018 10:13 | Pressemelding
Mr. Charman and Mr. Frudd to Join Sompo Holdings New Global Executive Committee PEMBROKE, Bermuda, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Sompo International Holdings Ltd. (Sompo International), a Bermuda-based specialty provider of property and casualty insurance and reinsurance, announced today that effective April 1, 2019, Mr. John Charman, currently Chairman of the Board of Directors and Chief Executive Officer of Sompo International, will be promoted to Chief Executive Officer of Overseas Insurance Business in Sompo Holdings, Inc. (Sompo Holdings). This segment of Sompo Holdings’ business currently represents more than 27% of Sompo Holdings Group’s adjusted profit, employing around 9,000 people in 30 countries and regions and is projected to have more than $10 billion in gross premiums by 2020. In such capacity, Mr. Charman will join the new Global Executive Committee of Sompo Holdings (Global ExCo) which will be established in April 2019 to provide expertise and input on group-wide st
LeddarTech Selects BlackBerry’s QNX Operating System for its Auto and Mobility LiDAR Platform18.12.2018 06:05 | Pressemelding
The QNX OS for Safety runs the software at the core of LeddarTech’s innovative automotive LiDAR development platform that enables the design of differentiated LiDAR solutions tailored to specific autonomous driving applications. QUEBEC CITY, Dec. 18, 2018 (GLOBE NEWSWIRE) -- LeddarTech , an industry leader providing the most versatile, scalable Auto and Mobility LiDAR Platform, today announced it has selected the QNX OS for Safety as the operating system for its LeddarSP Digital Signal Processing library. The LeddarSP software works in tandem with LeddarCore systems-on-chip to form the LeddarEngine, which is embedded at the heart of a variety of LiDAR sensor designs that enable ADAS and autonomous driving applications. “We believe that there is no safety without security,” said Grant Courville, VP of QNX Product Management and Strategy at BlackBerry. “We are thrilled to provide LeddarTech, an industry leader in LiDAR technology, with the reliable foundation necessary for building compe